STOCK TITAN

SANUWAVE HEALTH INC - SNWV STOCK NEWS

Welcome to our dedicated page for SANUWAVE HEALTH news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on SANUWAVE HEALTH stock.

SANUWAVE Health Inc. is a leading provider of noninvasive, biological response activating devices in regenerative medicine. They focus on repairing and regenerating tissue, musculoskeletal, and vascular structures using their PACE™ technology. With a portfolio of products that activate biologic signaling and angiogenic responses, SANUWAVE helps restore the body's natural healing processes and regeneration. Their products are used in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions.
Rhea-AI Summary

SANUWAVE Health reported record Q3 2024 financial results with revenues of $9.4 million, up 89% from Q3 2023. The company achieved a gross margin of 75.5% and GAAP Operating Income of $2.0 million. UltraMist® system sales increased to 124 units in Q3 2024, up from 55 in Q3 2023, while consumables revenue grew 75% to $5.4 million. Despite operational improvements, the company reported a net loss of $20.7 million, primarily due to derivative liabilities. SANUWAVE provides guidance for Q4 2024 revenue growth of 40-50% versus Q4 2023, projecting full-year 2024 revenues to exceed $32 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

SANUWAVE Health (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, announced it will host a conference call on November 8, 2024, at 8:30 AM (ET) to discuss its Q3 2024 financial results. Participants can join via toll-free number 1-800-267-6316 or international number 1-203-518-9783 using Conference ID: SANUWAVE. Materials will be available on the company's website, and a replay will be accessible through November 29, 2024, using replay access ID: 11157276.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

SANUWAVE Health announced a 1-for-375 reverse stock split effective from October 18, 2024. The common stock will trade on a split-adjusted basis under the symbol SNWV on the OTCQB, with a new CUSIP number, 80303D 305. This move will reduce the outstanding shares from approximately 1.18 billion to 3.15 million. Proportional adjustments will be made to equity awards, convertible notes, and warrants. No fractional shares will be issued; instead, fractional shares will be settled in cash. The reverse stock split will not change the total number of authorized shares or alter any stockholder's percentage interest in the company, except for adjustments due to fractional shares. Stockholders will receive transaction statements and information from the Securities Transfer regarding the exchange process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
Rhea-AI Summary

SANUWAVE Health (OTCQB: SNWV) reported record quarterly revenues for Q2 FY2024. Key highlights include:

- Q2 2024 revenues of $7.2 million, up 53% year-over-year
- Gross margin of 73%, slightly down from 74% in Q2 2023
- GAAP Operating Income of $2.0 million
- Net income of $6.6 million, compared to a net loss of $7.3 million in Q2 2023
- Adjusted EBITDA of $1.5 million, up from $171,000 in Q2 2023
- 72 UltraMist® systems sold, up from 49 in Q2 2023
- UltraMist® consumables revenue increased by 67% to $4.7 million

The company provided guidance for Q3 2024, expecting revenue growth of 65-75% compared to Q3 2023. SANUWAVE also secured approval for a reverse stock split and 100% participation in its note and warrant exchange offer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of FDA-approved wound care products, has announced a live conference call scheduled for August 13, 2024, at 8:30 AM (ET) to present their Q2 2024 financial results. Investors can access the call via toll-free (1-800-579-2543) or international (1-785-424-1789) numbers using the Conference ID: SANUWAVE. Alternatively, instant telephone access is available through a provided link.

Conference materials will be accessible on the company's website. A replay of the call will be available until September 3, 2024, using specific replay access numbers and ID. This event provides an opportunity for stakeholders to gain insights into SANUWAVE's recent financial performance and future outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.86%
Tags
conferences earnings
-
Rhea-AI Summary
SANUWAVE Health, Inc. announces record-breaking preliminary revenues of $5.7 to $5.9 million for Q1 2024, marking a 51% to 56% increase over Q1 2023. UltraMist revenues surged by over 55%, contributing 95% to total revenues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
Rhea-AI Summary
SANUWAVE Health, Inc. announces the hiring of Peter Sorensen as CFO, bringing extensive finance, forecasting, and capital markets experience to drive growth in the wound care business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
management
-
Rhea-AI Summary
SANUWAVE Health, Inc. reports record revenues for Q4 2023 and FY 2023, with significant growth in operating income. The company provides strong revenue growth guidance for Q1 2024 and FY 2024. UltraMIST® systems and consumables drive revenue growth, with a focus on profitable expansion. Adjusted EBITDA shows notable improvement, reflecting operational efficiencies. The company aims for rapid, profitable growth in the upcoming year, expecting substantial revenue increases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
-
Rhea-AI Summary
SANUWAVE Health, Inc. to present Q4 and FY2023 financial results in a live conference call on March 22, 2024. The company, known for its FDA-approved wound care products, invites participants to join the call or access it online. Materials will be available on the company website, with a replay option until April 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences earnings
Rhea-AI Summary
SANUWAVE Health, Inc. announces stockholders' approval of business combination with SEP Acquisition Corp. at a special meeting. 70.5% of eligible shares voted or abstained, with 99.3% voting 'for' the proposal. CEO Morgan Frank expresses satisfaction with the outcome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags

FAQ

What is the current stock price of SANUWAVE HEALTH (SNWV)?

The current stock price of SANUWAVE HEALTH (SNWV) is $22 as of November 22, 2024.

What is the market cap of SANUWAVE HEALTH (SNWV)?

The market cap of SANUWAVE HEALTH (SNWV) is approximately 26.0B.

What is SANUWAVE Health Inc. known for?

SANUWAVE specializes in noninvasive, biological response activating devices in the regenerative medicine field for tissue repair and regeneration.

What technology does SANUWAVE use in their products?

SANUWAVE's products are based on PACE™ technology, which activates biologic signaling and angiogenic responses.

In which medical areas does SANUWAVE's portfolio find application?

SANUWAVE's products are used in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions.

What is SANUWAVE's financial outlook for the future?

SANUWAVE expects significant revenue growth in 2024, with anticipated revenues over $30 million and a gross margin increase into the mid 70s.

What recent achievement did SANUWAVE announce for Q4 2023?

SANUWAVE announced preliminary revenues of $6.6 million to $6.8 million for Q4 2023, representing a new quarterly revenue record for the Company.

What was the outcome of SANUWAVE's special meeting of stockholders on February 21, 2024?

SANUWAVE stockholders approved the business combination with SEP Acquisition Corp., with 70.5% of all shares eligible to vote participating in the election.

What was SANUWAVE's Q1 2024 revenue performance like?

SANUWAVE announced preliminary revenues of $5.7 million to $5.9 million for Q1 2024, the highest Q1 revenues in company history.

How does SANUWAVE plan to communicate future updates?

SANUWAVE plans to provide business updates via conference calls, with details available on their website for investors to access.

What financial measures does SANUWAVE use to assess its performance?

SANUWAVE uses EBITDA and Adjusted EBITDA to evaluate its operating performance, with a focus on historical and prospective financial performance.

What are SANUWAVE's key areas of research and application for their patented technologies?

SANUWAVE focuses on wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions in applying and researching their patented energy transfer technologies.

SANUWAVE HEALTH INC

OTC:SNWV

SNWV Rankings

SNWV Stock Data

25.99B
8.21M
Medical Devices
Healthcare
Link
United States of America
Eden Prairie